Gomekli access in Lebanon: the MoPH-PDD named-patient pathway
How patients in the Lebanese Republic legally obtain Gomekli (mirdametinib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Lebanon access Gomekli (mirdametinib) for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas not amenable to complete resection through the MoPH-PDD named-patient pathway, a the Pharmacy and Drug Department of the Lebanese Ministry of Public Health-administered mechanism that allows a Lebanese-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in USD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Lebanese patients need Gomekli through the named-patient pathway
The Lebanese Republic operates a structured pharmaceutical regulatory environment. Gomekli (mirdametinib) is regulated through MoPH-PDD (the Pharmacy and Drug Department of the Lebanese Ministry of Public Health) channels, and a Lebanese family asking for Gomekli is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Gomekli's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Lebanon or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MoPH-PDD named-patient pathway is the mechanism that connects a Lebanese-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Gomekli is a small-molecule, selective, allosteric MEK1/MEK2 inhibitor that blocks RAS-MAPK pathway signalling in NF1-haploinsufficient Schwann-cell-derived tumours, shrinking plexiform neurofibromas, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Gomekli in Lebanon
Gomekli (mirdametinib; SpringWorks Therapeutics) is an oral selective allosteric MEK1/MEK2 inhibitor indicated for adult and paediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. The drug received FDA approval in February 2025 and is a recent entrant to the global register. As of 2026-05-31, no public MOPH record of a Lebanon marketing authorisation for mirdametinib has been observed on the MOPH registered drugs list.
Access for a Lebanese NF1 patient proceeds through the MOPH Directorate of Pharmacy as a compassionate-use named-patient file under Lebanese Pharmacy Profession Law No. 367/1994. The file specifies genetic confirmation of NF1 (NF1 variant or clinical NIH consensus criteria), volumetric imaging documentation of the symptomatic plexiform neurofibroma (MRI volumetry is the typical reference), the symptom inventory (pain, motor / sensory impairment, disfigurement, airway compromise), and prior medical / surgical management.
The dosing is weight-banded (administered as one of two strengths, 1 mg or 2 mg, taken twice daily 21 days on / 7 days off in a 28-day cycle) for paediatric patients and at fixed adult dosing. The file references the cycle plan, baseline ophthalmology assessment (the MEK-inhibitor class carries a retinal-vein-occlusion and retinal-pigment-epithelium-detachment signal), cardiac assessment (echocardiogram for LVEF baseline), and laboratory monitoring schedule.
Last verified by ARCH-74: 2026-05-31. Patient-organisation reporting on MEK inhibitors in Lebanon describes variable timelines tied to post-2019 currency-control constraints.
Named tertiary centres in Lebanon where Gomekli is dispensed
Mirdametinib for symptomatic plexiform neurofibromas requires a paediatric-or-adult neurofibromatosis MDT with neurology, oncology, plastic-surgery, and ophthalmology participation. The Lebanese centres equipped for this profile:
- American University of Beirut Medical Center (AUBMC), Beirut - Departments of Paediatric and Adult Neurology, Medical Oncology, and Plastic Surgery; the NF1 MDT operates as a virtual clinic with AUBMC as the principal coordinator.
- Hotel-Dieu de France de Beyrouth (USJ), Beirut - paediatric neurology and adult neuro-oncology; principal francophone academic centre.
- Saint George Hospital University Medical Center, Beirut - paediatric and adult neurology.
- Children's Cancer Center of Lebanon (CCCL) at AUBMC, Beirut - paediatric specialty centre primarily for haemato-oncology; NF1 cross-referrals are routine where plexiform neurofibroma overlaps with malignant peripheral-nerve-sheath-tumour risk.
- LAU Medical Center - Rizk Hospital, Beirut - paediatric and adult neurology service.
Ophthalmology baseline and serial monitoring is on-site at AUBMC and Hotel-Dieu; smaller hospitals refer ophthalmology surveillance to AUBMC. Echocardiogram baseline is in-house at all five centres.
Local pricing reference for Gomekli in Lebanon
US WAC reference for Gomekli (mirdametinib, 1 mg and 2 mg oral capsules) is in the order of USD 27,000 to USD 32,000 per 28-day cycle at the FDA-labelled weight-banded twice-daily 21-on-7-off regimen for a paediatric patient at the upper weight band. The annual reference at full-year dosing is in the order of USD 350,000 to USD 400,000. Source: Gomekli FDA Prescribing Information.
Post-2019 Lebanon prices specialty medicines in fresh USD. We quote Gomekli in USD throughout. No public LBP reference price for mirdametinib has been observed on MOPH or hospital-pharmacy lists as of 2026-05-31.
Price snapshot date: 2026-05-31. Concomitant monitoring (ophthalmology, echocardiogram, hepatic and CK monitoring) is locally sourced.
Country-specific access barriers for Gomekli in Lebanon
The principal access barrier for mirdametinib in Lebanon is funding under post-crisis fiscal constraints. The MOPH Pharmaceutical Aid Programme's capacity to fund novel rare-disease oncology-adjacent therapies has been materially constrained; current eligibility for NF1 plexiform neurofibroma indication is not consistently documented. SpringWorks operates regional patient-access programmes; Lebanon-specific eligibility shifts with programme parameters and requires direct query at file initiation.
Private-insurance coverage of mirdametinib is policy-specific. Lebanese private insurers (MEDGulf, Bankers Insurance, AROPE, Allianz SNA, AXA Middle East) tightened specialty-drug coverage with USD-denominated pricing pressure during the crisis; current coverage of MEK inhibitors typically requires advance pre-authorisation and is policy-dependent. The dominant funding pattern is patient self-pay in fresh USD supplemented by charitable hospital channels at AUBMC.
For Syrian and Palestinian refugee paediatric NF1 patients UNHCR and UNRWA-supported pathways operate parallel to MOPH; mirdametinib has not been a routine UNHCR-supplied product as of 2026-05-31, although programmatic decisions change and should be verified at file initiation.
The dosing-cycle structure (21 days on / 7 days off in a 28-day cycle) and the chronic-therapy nature of NF1 management dictates that each MOPH permit covers a defined supply window; patients on chronic therapy re-apply per cycle. Ambient-storage oral capsules simplify customs handling; cold-chain is not applicable.
Recent local regulatory news touching Gomekli or its drug class in Lebanon
No MOPH bulletin specifically naming mirdametinib or the MEK-inhibitor class has been observed in the last twelve months on the MOPH news and circulars page as of 2026-05-31. Adjacent context:
- FDA approval of mirdametinib in February 2025 is the most recent regulatory event for the drug; class-level MEK-inhibitor safety updates (ocular events in particular) are tracked. Source: FDA Drugs@FDA database.
- MOPH continues iterative Pharmaceutical Aid Programme communications under post-crisis fiscal constraints; rare-disease aid eligibility shifts have occurred several times over 2024-2026. Source: MOPH.
What your physician needs to provide
For a Lebanese-licensed specialist prescribing Gomekli through the MoPH-PDD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas not amenable to complete resection, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Gomekli is the appropriate next step given a small-molecule, selective, allosteric MEK1/MEK2 inhibitor that blocks RAS-MAPK pathway signalling in NF1-haploinsufficient Schwann-cell-derived tumours, shrinking plexiform neurofibromas.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Gomekli (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Lebanese license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Gomekli in Lebanon
Will out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Gomekli is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MoPH-PDD? The MoPH-PDD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MoPH-PDD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Lebanese-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Lebanese Order of Physicians (Beirut or Tripoli branch) and the MoPH Pharmacy and Drug Department verifies the active license; the MoPH-PDD application records both the prescribing physician and the dispensing facility.
Can I receive Gomekli at home? The dispensing facility must be Lebanese-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Gomekli cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MoPH-PDD, and we do not replace your dispensing pharmacy. For Gomekli specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Lebanon, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Gomekli case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MoPH-PDD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Lebanese tertiary specialty care concentrates at AUBMC, Hotel-Dieu de France, LAU Medical Center-Rizk Hospital, Clemenceau Medical Center, and Mount Lebanon Hospital in Beirut and Hazmieh; following the post-2019 currency crisis, specialty-medicine pricing is quoted predominantly in fresh US dollars, and the MoPH Pharmacy and Drug Department named-patient import authorisation is the standard mechanism for unregistered specialty medicines.
Next step
If your Lebanese physician has prescribed Gomekli and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.